Preliminary program thematic sessions
 

Opening lecture: Anthony Hickey, RTI

Session 1:  Formulations and devices
Chair: Paolo Colombo, University of Parma

  • Formulation of dry powders for inhalation to achieve tunable anti-microbial drug release in the lung 
    Pavan Muttil, University of New Mexico
  • Multi-antimicrobial-drug compatible dry powder inhalers  
    Anne de Boer, University of Groningen
  • Preliminary biopharmaceutical classification of antibiotic drugs for pulmonary delivery                                                                                      Sandrine Marchand, University of Poitiers (submitted abstract)

Session 2:  Submitted abstracts session
Chair: Erik Frijlink, University of Groningen

  • On-stage presentations by early career researchers (submitted abstracts)

Session 3: Development and implementation

  • The quest for potentiators for antimicrobial drugs 
    Jurriaan de Steenwinkel, Erasmus Medical Centre Rotterdam
  • Implementation of a new drug (regime) into a TB treatment guideline    
    Dennis Falzon, WHO
  • Development of inhaled pyrazinoic acid to treat tuberculosis                                                                                                                                          Miriam Braunstein, University of North Carolina School of Medicine (submitted abstract)                                                                               
  • A phase-1 clinical trial design for inhalable particles containing isoniazid and rifabutin                                                                                          Amit Misra, Central Drug Research Institute Lucknow (submitted abstract)  

Session 4: Preclinical, models, and modelling
Chair: Rany Condos, New York University

  • The power of in vitro models in the continuous battle against M. tuberculosis
    Tawanda Gumbo, Baylor Research Institute
  • Pharmacokinetic modelling and inhalation of anti TB drugs                                                                                                                                         Ulrika Simonsson, Uppsala University
  • The value of animal models in the development of inhaled TB therapies                                                                                                                    Lucila Garcia-Contreras, University of Oklahoma
  • The role of Functional Respiratory Imaging (FRI) in TB treatment
    Wim Vos, consultant
  • PK/PD type modeling approach to support time-kill data interpretation of cefoxitin for the treatment of Mycobacterium abscessus  Julien Buyck, University of Poitiers (submitted abstract) 
  • A novel antibiotic strategy for Mycobacterium tuberculosis based on high resolution microscopy of DNA condensation                Nicole van der Wel, Amserdam University Medical Centre (submitted abstract)

Session 5: Clinical trials and use
Chairs: Edward Nardell, Harvard Medical School & Tjip van der Werf, Beatrixoord (UMCG)

  • The added value of pharmacokinetics and pharmacodynamics for old and repurposed TB drugs                                                                        Simon Tiberi, Barts Health NHS Trust
  • How to choose and evaluate a new treatment regimen for MDR-TB                                                                                                                                Martin Grobusch, Amsterdam Medical Center / University of Amsterdam
  • The pros and cons of inhalation of new and current TB drugs
    Onno Akkerman, University Medical Center Groningen